Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in Interest ReceivablesChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresLong-Term Debt IssuancesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amylyx Pharmaceuticals (AMLX) Gains from Sales and Divestitures (2023 - 2025)

Amylyx Pharmaceuticals has reported Gains from Sales and Divestitures over the past 3 years, most recently at $1.2 million for Q4 2025.

  • Quarterly results put Gains from Sales and Divestitures at $1.2 million for Q4 2025, up 68.82% from a year ago — trailing twelve months through Dec 2025 was $1.2 million (up 68.82% YoY), and the annual figure for FY2025 was $1.2 million, up 68.82%.
  • Gains from Sales and Divestitures for Q4 2025 was $1.2 million at Amylyx Pharmaceuticals, up from $1.2 million in the prior quarter.
  • Over the last five years, Gains from Sales and Divestitures for AMLX hit a ceiling of $1.2 million in Q4 2025 and a floor of $146694.0 in Q1 2023.
  • Median Gains from Sales and Divestitures over the past 3 years was $477789.5 (2024), compared with a mean of $534057.0.
  • Peak annual rise in Gains from Sales and Divestitures hit 306.16% in 2024, while the deepest fall reached 57.77% in 2024.
  • Amylyx Pharmaceuticals' Gains from Sales and Divestitures stood at $185045.0 in 2023, then surged by 284.89% to $712218.0 in 2024, then skyrocketed by 68.82% to $1.2 million in 2025.
  • The last three reported values for Gains from Sales and Divestitures were $1.2 million (Q4 2025), $1.2 million (Q3 2025), and $775162.0 (Q2 2025) per Business Quant data.